{Reference Type}: Journal Article
{Title}: Intraperitoneal Irrigation Chemotherapy with Lobaplatin in Locally Advanced Gastric Cancer: A Special Type of Abdominal Chemotherapy.
{Author}: Zhang J;Wang P;Sun Y;Bai X;Zhong Y;
{Journal}: Asian Pac J Cancer Prev
{Volume}: 25
{Issue}: 7
{Year}: 2024 Jul 1
暂无{DOI}: 10.31557/APJCP.2024.25.7.2409
{Abstract}: <B>BACKGROUND: </B>This study evaluated the safety and efficiency of intraperitoneal irrigation chemotherapy with lobaplatin for the treatment of advanced gastric cancer (GC).<BR><B>METHODS: </B>A total of 56 locally advanced GC patients (experimental group) who received intraoperative intraperitoneal irrigation chemotherapy in addition to undergoing radical D2 surgery were matched 1:1 based on 8 covariates to 56 patients without drug treatment (control group). Clinical data were collected and analyzed.<BR><B>RESULTS: </B>The two groups were well balanced in basic characteristics and had comparable clinical indices. All patients had similar time to first flatus (2.8 ± 0.3 vs. 2.9 ± 0.3 d, P = 0.076), time to first oral intake (3.5 ± 3.4 vs. 4.1 ± 4.6 d, P = 0.439), and duration of postoperative hospitalization (9.1 ± 3.2 vs. 9.6 ± 4.0 d, P = 0.446). There were no significant differences in postoperative complications including anastomotic and duodenal stump leakage, abdominal and anastomotic bleeding, seroperitoneum, and incision infection between the experimental and control groups (P > 0.05). The rates of chemotherapy-related side effects including allergic reaction, neurotoxicity, diarrhea, and nausea/vomiting were also similar between the two groups, and there were no abnormalities in leukocyte and platelet levels and liver and renal function during the first 5 days after surgery.<BR><B>CONCLUSIONS: </B>Intraperitoneal irrigation chemotherapy with lobaplatin is safe for patients with advanced gastric cancer.